<DOC>
	<DOCNO>NCT01478490</DOCNO>
	<brief_summary>The study aim compare blood urine concentration mirabegron ( YM178 ) healthy poor extensive metabolizers CYP2D6 evaluate blood level metoprolol change whilst dose time daily miragebron .</brief_summary>
	<brief_title>To Compare Blood Urine Concentrations Mirabegron ( YM178 ) Healthy Poor Extensive Metabolizers CYP2D6 Assess Effect Mirabegron Metabolism Metoprolol</brief_title>
	<detailed_description>The study open label , single center study . All subject genotyped CYP2D6 study . Genotype expression confirm dextromethorphan phenotyping . Part I : The pharmacokinetic profile single dose YM178 compare 8 healthy male subject genotyped phenotyped poor metaboliser ( PM ) CYP2D6 8 healthy male subject genotyped phenotyped extensive metaboliser ( EM ) CYP2D6 . Part II : The effect YM178 model substrate CYP2D6 metoprolol evaluate , use cross-over design , 12 healthy male subject genotyped phenotyped EM CYP2D6 .</detailed_description>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>For Part I : Subject genotyped phenotyped CYP2D6 Body weight 60 100 kg Body Mass Index less equal 30 kg/m2 For Part II : Subject genotyped phenotyped extensive metaboliser CYP2D6 Body weight 60 100 kg Body Mass Index less equal 30 kg/m2 Known suspect hypersensitivity βadrenergic receptor agonists constituent formulation use Any clinically significant history asthma , eczema , allergic condition previous severe hypersensitivity drug Any clinically significant history upper gastrointestinal symptom ( nausea , vomit , abdominal discomfort upset , heartburn ) 4 week prior admission Research Unit Any clinically significant history disease disorder gastrointestinal , cardiovascular , respiratory , renal , hepatic , neurological , dermatological , psychiatric metabolic Any clinically significant abnormality follow investigator 's review prestudy physical examination , ECG clinical laboratory test QTc interval &gt; 430 msec Abnormal pulse rate measurement ( &lt; 40 &gt; 90 bpm ) take manual counting prestudy visit subject rest supine position 5 min Abnormal blood pressure measurement take prestudy visit subject rest supine position 5 min follow : systolic blood pressure &lt; 95 &gt; 160 mmHg ; diastolic blood pressure &lt; 40 &gt; 95 mmHg Positive orthostatic test screening i.e . symptom dizziness , lightheadedness etc . and/or fall ≥ 20 mmHg systolic blood pressure 2 min standing ( precede 5 min . supine rest ) and/or increase pulse rate ≥ 20 bpm Regular use prescribe OTC drug except paracetamol 3 g/day , 4 week prior admission Research Unit OR use drug 2 week prior admission Research Unit</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Pharmacokinetics ,</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Metoprolol</keyword>
	<keyword>CYP2D6</keyword>
	<keyword>Phase 1</keyword>
</DOC>